[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"XueQing Yu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100306063",false,"NCT03264352","Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","IPAD","Inclusion Criteria:\n\n* irrespective of sex;\n* aged between 45 and 79 years;\n* with office-measured seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic;\n* diagnosed of type 2 diabetes mellitus (T2DM), currently on diabetic therapy;\n* informed consent provided and long-term follow-up possible\n\nExclusion Criteria:\n\n* poor control of blood glucose, HbA1c \\> 10.0%\n* administration of any antihypertensive medications within 1 month;\n* a history of hypoglycemic coma \u002F seizure;\n* confirmed diagnosis of type 1 diabetes mellitus;\n* alanine-aminotransferase (ALT) or aspartate-aminotransferase (AST) over three times the upper limit of normal;\n* estimated glomerular filtration rate \\\u003C 45 ml\u002Fmin\u002F1.73m2;\n* a history of congestive heart failure with left ventricular ejection fraction \\\u003C 40%;\n* coronary artery disease requiring RAS blockers for secondary prevention;\n* acute on-set of stroke within 6 months prior to randomization;\n* a ratio of urinary albumin (in mg\u002FL) to urinary creatinine (in g\u002FL) (ACR) ≥ 300 mg\u002Fg;\n* known contraindications for the active study medications;\n* a history of psychological or mental disorder;\n* pregnancy or currently planning to have babies or lactation;\n* severe diseases such as severe heart diseases;\n* an expected residual life span less than 3 years;\n* a malignancy that clinical investigators consider as unsuitable to participate;\n* currently participating in another clinical trial.","ALL","45 Years","79 Years",{"count":19,"type":20},11414,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular and cerebrovascular events. Diabetic patients with hypertension benefit from BP lowering treatment. The present trial, IPAD in brief, is a randomized, open-label, parallel-designed, multicenter study involving nearly 12,000 patients to be recruited and to be followed up for a median of four years. IPAD tests the hypothesis that antihypertensive medications in adults with type 2 diabetes, whose seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic, results in 20% difference in the incidence of major adverse cardiovascular and cerebrovascular events. During follow-up for participants in the intensive group, the sitting systolic pressure should be decreased to below 120 mm Hg, by titration and combination of the study medications of an angiotensin type-1 receptor blocker Allisartan (240 mg\u002Fday), a dihydropyridine calcium-channel blocker (amlodipine 5-10 mg\u002Fday), and\u002For other medications if necessary. For those in the standard group, the sitting systolic pressure should be monitored and controlled below 140 mm Hg.",[26,27,28,29,30],"Diabetes Mellitus, Type 2","Adverse Event","Blood Pressure","Prehypertension","Cardiovascular Risk Factor","RECRUITING","2025-03-10",{"date":34,"type":35},"2025-03-12","ACTUAL",{"date":37,"type":35},"2018-02-01",{"date":39,"type":20},"2025-09",{"name":41,"class":42},"XueQing Yu","OTHER",""]